Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2013, Article ID 184539, 7 pages
http://dx.doi.org/10.1155/2013/184539
Review Article

Uncoupling of VEGF with Endothelial NO as a Potential Mechanism for Abnormal Angiogenesis in the Diabetic Nephropathy

1TMK Project, Kyoto University Graduate School of Medicine, Kyoto 606-8397, Japan
2Department of Nephrology, Nagoya University Graduate School of Medicine, 466-8550, Japan
3Division of Renal Diseases and Hypertension, University of Colorado Denver, Aurora, CO 80045, USA

Received 26 September 2013; Accepted 7 November 2013

Academic Editor: Keizo Kanasaki

Copyright © 2013 Takahiko Nakagawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Østerby and G. Nyberg, “New vessel formation in the renal corpuscles in advanced diabetic glomerulopathy,” Journal of Diabetic Complications, vol. 1, no. 4, pp. 122–127, 1987. View at Google Scholar · View at Scopus
  2. B. Hohenstein, B. Hausknecht, K. Boehmer, R. Riess, R. A. Brekken, and C. P. M. Hugo, “Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man,” Kidney International, vol. 69, no. 9, pp. 1654–1661, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Kanesaki, D. Suzuki, G. Uehara et al., “Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy,” The American Journal of Kidney Diseases, vol. 45, no. 2, pp. 288–294, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Østerby, H.-J. Bangstad, G. Nyberg, and S. Rudberg, “On glomerular structural alterations in type-1 diabetes: companions of early diabetic glomerulopathy,” Virchows Archiv, vol. 438, no. 2, pp. 129–135, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. W. Min and N. Yamanaka, “Three-dimensional analysis of increased vasculature around the glomerular vascular pole in diabetic nephropathy,” Virchows Archiv A, vol. 423, no. 3, pp. 201–207, 1993. View at Google Scholar · View at Scopus
  6. H. Wehner and G. Nelischer, “Morphometric investigations on intrarenal vessels of streptozotocin-diabetic rats,” Virchows Archiv A, vol. 419, no. 3, pp. 231–235, 1991. View at Google Scholar · View at Scopus
  7. R. Østerby, A. Hartmann, and H.-J. Bangstad, “Structural changes in renal arterioles in type I diabetic patients,” Diabetologia, vol. 45, no. 4, pp. 542–549, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. J. R. Nyengaard and R. Rasch, “The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes,” Diabetologia, vol. 36, no. 3, pp. 189–194, 1993. View at Google Scholar · View at Scopus
  9. M. Guo, S. D. Ricardo, J. A. Deane, M. Shi, L. Cullen-McEwen, and J. F. Bertram, “A stereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy,” Journal of Anatomy, vol. 207, no. 6, pp. 813–821, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Ichinose, Y. Maeshima, Y. Yamamoto et al., “2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice,” Diabetes, vol. 55, no. 5, pp. 1232–1242, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. H. J. Baelde, M. Eikmans, D. W. P. Lappin et al., “Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss,” Kidney International, vol. 71, no. 7, pp. 637–645, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Nakagawa, W. Sato, O. Glushakova et al., “Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 18, no. 2, pp. 539–550, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Ostendorf, U. Kunter, F. Eitner et al., “VEGf165 mediates glomerular endothelial repair,” Journal of Clinical Investigation, vol. 104, no. 7, pp. 913–923, 1999. View at Google Scholar · View at Scopus
  14. D.-H. Kang, J. Hughes, M. Mazzali, G. F. Schreiner, and R. J. Johnson, “Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function,” Journal of the American Society of Nephrology, vol. 12, no. 7, pp. 1448–1457, 2001. View at Google Scholar · View at Scopus
  15. D.-H. Kang, Y.-G. Kim, T. F. Andoh et al., “Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor,” The American Journal of Physiology—Renal Physiology, vol. 280, no. 4, pp. F727–F736, 2001. View at Google Scholar · View at Scopus
  16. M. E. Cooper, D. Vranes, S. Youssef et al., “Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes,” Diabetes, vol. 48, no. 11, pp. 2229–2239, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. W. Sato, T. Kosugi, L. Zhang et al., “The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy,” Laboratory Investigation, vol. 88, no. 9, pp. 949–961, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. N. H. Kim, J. H. Oh, J. A. Seo et al., “Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy,” Kidney International, vol. 67, no. 1, pp. 167–177, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. A. S. de Vriese, R. G. Tilton, M. Elger, C. C. Stephan, W. Kriz, and N. H. Lameire, “Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes,” Journal of the American Society of Nephrology, vol. 12, no. 5, pp. 993–1000, 2001. View at Google Scholar · View at Scopus
  20. B. F. Schrijvers, A. S. de Vriese, R. G. Tilton et al., “Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes,” Hormone and Metabolic Research, vol. 37, no. 1, pp. 21–25, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. C.-H. Ku, K. E. White, A. D. Cas et al., “Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice,” Diabetes, vol. 57, no. 10, pp. 2824–2833, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. Q. Zhao, K. Egashira, S. Inoue et al., “Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis,” Circulation, vol. 105, no. 9, pp. 1110–1115, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Dunk and A. Ahmed, “Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells,” The American Journal of Pathology, vol. 158, no. 1, pp. 265–273, 2001. View at Google Scholar · View at Scopus
  24. S. V. Brodsky, A. M. Morrishow, N. Dharia, S. S. Gross, and M. S. Goligorsky, “Glucose scavenging of nitric oxide,” The American Journal of Physiology—Renal Physiology, vol. 280, no. 3, pp. F480–F486, 2001. View at Google Scholar · View at Scopus
  25. R. Bucala, K. J. Tracey, and A. Cerami, “Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes,” Journal of Clinical Investigation, vol. 87, no. 2, pp. 432–438, 1991. View at Google Scholar · View at Scopus
  26. U. M. Khosla, S. Zharikov, J. L. Finch et al., “Hyperuricemia induces endothelial dysfunction,” Kidney International, vol. 67, no. 5, pp. 1739–1742, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Xiong, M. Lei, S. Fu, and Y. Fu, “Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes,” Life Sciences, vol. 77, no. 2, pp. 149–159, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Ceriello, F. Mercuri, L. Quagliaro et al., “Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress,” Diabetologia, vol. 44, no. 7, pp. 834–838, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Noiri, H. Satoh, J.-I. Taguchi et al., “Association of eNOS Glu298Asp polymorphism with end-stage renal disease,” Hypertension, vol. 40, no. 4, pp. 535–540, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Liu, K. P. Burdon, C. D. Langefeld et al., “T-786C polymorphism of the endothelial nitric oxide synthase gene is associated with albuminuria in the diabetes heart study,” Journal of the American Society of Nephrology, vol. 16, no. 4, pp. 1085–1090, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Neugebauer, T. Baba, and T. Watanabe, “Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes,” Diabetes, vol. 49, no. 3, pp. 500–503, 2000. View at Google Scholar · View at Scopus
  32. Y. Shin Shin, S. H. Baek, K. Y. Chang et al., “Relations between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy,” Diabetes Research and Clinical Practice, vol. 65, no. 3, pp. 257–265, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Zanchi, D. K. Moczulski, L. S. Hanna, M. Wantman, J. H. Warram, and A. S. Krolewski, “Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism,” Kidney International, vol. 57, no. 2, pp. 405–413, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Degen, S. Schmidt, and E. Ritz, “A polymorphism in the gene for the endothelial nitric oxide synthase and diabetic nephropathy,” Nephrology Dialysis Transplantation, vol. 16, no. 1, p. 185, 2001. View at Google Scholar · View at Scopus
  35. S. Lin, H. Qu, and M. Qiu, “Allele A in intron 4 of ecNOS gene will not increase the risk of diabetic nephropathy in type 2 diabetes of Chinese population,” Nephron, vol. 91, no. 4, p. 768, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. J. D. Rippin, A. Patel, N. D. Belyaev, G. V. Gill, A. H. Barnett, and S. C. Bain, “Nitric oxide synthase gene polymorphisms and diabetic nephropathy,” Diabetologia, vol. 46, no. 3, pp. 426–428, 2003. View at Google Scholar · View at Scopus
  37. T. Shimizu, T. Onuma, R. Kawamori, Y. Makita, and Y. Tomino, “Endothelial nitric oxide synthase gene and the development of diabetic nephropathy,” Diabetes Research and Clinical Practice, vol. 58, no. 3, pp. 179–185, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Hohenstein, C. P. M. Hugo, B. Hausknecht, K. P. Boehmer, R. H. Riess, and R. E. Schmieder, “Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy,” Nephrology Dialysis Transplantation, vol. 23, no. 4, pp. 1346–1354, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Sugimoto, K. Shikata, M. Matsuda et al., “Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy,” Diabetologia, vol. 41, no. 12, pp. 1426–1434, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. S. V. Brodsky, S. Gao, H. Li, and M. S. Goligorsky, “Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 283, no. 5, pp. H2130–H2139, 2002. View at Google Scholar · View at Scopus
  41. R. Komers, W. E. Schutzer, J. F. Reed et al., “Altered endothelial nitric oxide synthase targeting and conformation and caveolin-1 expression in the diabetic kidney,” Diabetes, vol. 55, no. 6, pp. 1651–1659, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Borch-Johnsen, S. Kreiner, and T. Deckert, “Mortality of type 1 (insulin-dependent) diabetes mellitus in Denmark: a study of relative mortality in 2930 Danish type 1 diabetic patients diagnosed from 1933 to 1972,” Diabetologia, vol. 29, no. 11, pp. 767–772, 1986. View at Google Scholar · View at Scopus
  43. T. Nakagawa, W. Sato, Y. Y. Sautin et al., “Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy,” Journal of the American Society of Nephrology, vol. 17, no. 3, pp. 736–745, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Sato, K. Tanabe, T. Kosugi et al., “Selective stimulation of VEGFR2 accelerates progressive renal disease,” The American Journal of Pathology, vol. 179, no. 1, pp. 155–166, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. H.-J. Grone, M. Simon, and E. F. Grone, “Expression of vascular endothelial growth factor in renal vascular disease and renal allografts,” The Journal of Pathology, vol. 177, no. 3, pp. 259–267, 1995. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Shulman, S. Rosen, K. Tognazzi, E. J. Manseau, and L. F. Brown, “Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases,” Journal of the American Society of Nephrology, vol. 7, no. 5, pp. 661–666, 1996. View at Google Scholar · View at Scopus
  47. G. A. Sivaskandarajah, M. Jeansson, Y. Maezawa, V. Eremina, H. J. Baelde, and S. E. Quaggin, “Vegfa protects the glomerular microvasculature in diabetes,” Diabetes, vol. 61, no. 11, pp. 2958–2966, 2012. View at Google Scholar
  48. T. Kosugi, M. Heinig, T. Nakayama, S. Matsuo, and T. Nakagawa, “eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists,” The American Journal of Pathology, vol. 176, no. 2, pp. 619–629, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Perico, S. C. Amuchastegui, V. Colosio, G. Sonzogni, T. Bertani, and G. Remuzzi, “Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started,” Journal of the American Society of Nephrology, vol. 5, no. 4, pp. 1139–1146, 1994. View at Google Scholar · View at Scopus
  50. W. Pichaiwong, K. L. Hudkins, T. Wietecha et al., “Reversibility of structural and functional damage in a model of advanced diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 24, no. 7, pp. 1088–1102, 2013. View at Google Scholar
  51. K. Tanabe, M. A. Lanaspa, W. Kitagawa et al., “Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse,” The American Journal of Physiology—Renal Physiology, vol. 302, no. 9, pp. F1151–F1161, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Imanishi, N. Okada, Y. Konishi et al., “Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 14, no. 1, pp. 67–73, 2013. View at Google Scholar
  53. P. Fioretto, C. D. A. Stehouwer, M. Mauer et al., “Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure,” Diabetologia, vol. 41, no. 2, pp. 233–236, 1998. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Jensen, “Increased plasma concentration of von Willebrand factor in insulin dependent diabetics with incipient nephropathy,” The British Medical Journal, vol. 298, no. 6665, pp. 27–28, 1989. View at Google Scholar · View at Scopus
  55. T. Jensen, J. Bjerre-Knudsen, B. Feldt-Rasmussen, and T. Deckert, “Features of endothelial dysfunction in early diabetic nephropathy,” The Lancet, vol. 1, no. 8636, pp. 461–463, 1989. View at Google Scholar · View at Scopus